Diffuse large B-cell lymphomas - BHS
Transcript of Diffuse large B-cell lymphomas - BHS
![Page 1: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/1.jpg)
Diffuse large B-cell lymphomas
G. Verhoef, MD, PhD
University Hospital Leuven
BHS, March 9, 2013
![Page 2: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/2.jpg)
Case• A 72-year-old previously healthy man presented with acute abdominal
pain and a 15 kg weight loss.• Positron emission tomography demonstrated [18F]fluorodeoxyglucose-
avid mesenteric lymphadenopathy, with evidence of bowel compression near a 3x3 cm lymph node and mediastinal lymphadenopathy
• Bone marrow biopsy was negative, LDH normal, viral serology negative
![Page 3: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/3.jpg)
CD20 Ki67
Diffuse Large B-cell Lymphoma
![Page 4: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/4.jpg)
Diffuse large B-cell lymphoma: 30% of NHL Cases
Follicular(25%)
Small lymphocytic(7%)
MALT typemarginal zoneB cell (7.5%)
Nodal typemarginal zoneB cell (< 2%)
Lymphoplasmacytic(< 2%)
Diffuselarge B cell
(30%)
T and NK cell(12%)
Other subtypes(9%)
Burkitt(2.5%)
Mantle cell(6%)
Lichtman. Williams Hematology, 7th edition. 2006;1408
4
![Page 5: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/5.jpg)
DLBCL
• Classification and subtypes of DLBCL
• Prognostic factors
• Treatment guidelines
![Page 6: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/6.jpg)
“Higby” classification for Lymphomas(NYJM, 1979)
I. Good ones
II. Not-so-good ones
III. Really bad ones
IV. Ones that are not what they seem
![Page 7: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/7.jpg)
Aggressive B-cell lymphomas in WHO Classification 2008
Entities
Diffuse large B-cell lymphoma (DLBCL), not otherwise specifiedCommon morphologic variants
CentroblasticImmunoblasticAnaplastic
Rare morphological variantsMolecular subgroups
Germinal centre B-cell-like (GCB)Activated B-cell-like (ABC)
Immunohistochemical subgroupsCD-5-positive DLBCLGerminal Centre B-cell like (CCB)Non-germinal centre B-cell-like (non-GCB)
Diffuse large B-cell lymphoma subtypesprimary DLBCL of the CNSPrimary cutaneous DLBCL, leg typeT cell/histiocyte rich large B-cell lymphomaEBV+ DLBCL of the elderly*
![Page 8: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/8.jpg)
Aggressive B-cell lymphomas in WHO Classification 2008
Other lymphomas of large B-cells
Primary mediastinal (thymic) large B-cell lymphomaIntravascular large B-cell lymphomaDLBCL associated with chronic inflammationLymphomatoid granulomatosisALK-positive large B-cell lymphomaPlasmoblastic lymphomaLarge B-cell lymphoma arising in HHV-8-associated multicentric Castleman DiseasePrimary effusion lymphoma
Borderline cases
B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BLB-cell lymphoma, unclassifiable, with features intermediate between DLBCL and HL
![Page 9: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/9.jpg)
DLBCL, NOSDLBCL subtypes in specific anatomic sites
• Primary DLBCL of the central nervous system (Daan Dierickx)– Different clinical presentation
– Relation between intraocular disease
– GEP studies demonstrated some unique features
– Link between testis DLBCL (?)
– Different treatment and outcome
• Primary cutaneous DLBCL, leg type
• Intravascular large B-cell lymphoma
![Page 10: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/10.jpg)
DLBCL, NOSDLBCL subtypes in specific anatomic sites
• Primary cutaneous DLBCL, leg type– Often a better prognosis
• Intravascular large B-cell lymphoma– Rare form of DLBCL
– Presence of large B cells only in the lumens of small vessels, particularly capillaries
– Lymph node involvement is rare
– Neurological symptoms
– Often not diagnosed until autopsy
– Most often ABC phenotype and CD5-positive
![Page 11: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/11.jpg)
Case presentation
• 41-year old woman
• Longstanding B-symptoms
• Progressive encefalopathy
• Tachypnoe and tachycardia
• Labo: LDH↑↑↑
![Page 12: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/12.jpg)
A
Intravascular lymphoma, stage IVE
![Page 13: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/13.jpg)
Courtesy department of PathologyGlomerular capillaries containing large irregular cellswith infiltration of the surrounding interstitium
![Page 14: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/14.jpg)
Courtesy department of PathologyCD20 immunostaining of tumour cells in interstitiumand glomerular capillaries
![Page 15: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/15.jpg)
Intravascular lymphoma
• Rare subtype of extra-nodal diffuse large B-cell lymphoma– Characterized by proliferation of neoplastic lymphoid cells in the
lumina of small vessels, particularly capillaries
• Can effect virtually every organ system– CNS, skin, lung, kidney, adrenals, BM
• Most frequent clinical manifestations– Encefalopathy
– Cutaneous lesions
– Fever of unknown origin
– Interstitial lung disease, pulmonary hypertension, adrenal failure, nephrotic syndrome……
![Page 16: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/16.jpg)
Intravascular lymphoma
• Diagnosis is often only made post-mortem
• Pathophysiology:
– Lack of CD29 and CD54 adhesion molecules
• Prognosis:
– Extremely aggressive
– Because of frequent delay in diagnosis???
![Page 17: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/17.jpg)
T-cell/histiocyte-rich large B-cell lymphoma
• Morphological variant, but with manydistinctive clinical features
– Aggressive
– Often advanced stage
– Splenomegaly and BM involvement
– Relationship with nodular lymphocytepredominant Hodgkin lymphoma (NLPHL)
– NLPHL may progress to de novo T/HRLBCL
![Page 18: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/18.jpg)
Courtesy T. Tousseyn
Small number of large, atypical cells,surrounded by histiocytesand small lymphocytes
![Page 19: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/19.jpg)
CD20
Courtesy T. Tousseyn
![Page 20: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/20.jpg)
CD20 CD68
Courtesy T. Tousseyn
![Page 21: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/21.jpg)
![Page 22: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/22.jpg)
Primary Mediastinal large B-cell lymphoma (PMBL)
Sheets of large cells with abundant pale cytoplasm
![Page 23: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/23.jpg)
Primary Mediastinal LBCL (PMBL)
Associated interstial fibrosis
![Page 24: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/24.jpg)
Primary Mediastinal large B-cell lymphoma (PMBL)
• Common in adolescents and young adults
• Tumor is thought to be derived frommedullary B cells within the thymus gland
• CD20 and CD79a without surfaceimmunoglobulin
• CD30 is often positive, cREL1, TRAF1
• A GEP differing from DLBCL and resembles cHL
• Upregulation of NFƙB pathway
![Page 25: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/25.jpg)
DLBCL and MLBCL genes
![Page 26: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/26.jpg)
EBER in situCD20H&E
Elderly patient, 65 year old
![Page 27: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/27.jpg)
EBV-positive DLBCL of the elderly
• Provisional entity, first described in elderly Japanese patients
• Patients are generally >50 years without any knownimmunodeficiency or prior lymphoma
• Clinical behavior is aggressive with frequent extranodalpresentation
• Poor prognosis
• Sometimes overlap with classical Hodgkin with HRS-like cells
• Other variant: EBV-positive DLBCL associated with chronicinflammation
![Page 28: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/28.jpg)
DLBCL, NOSDLBCL, specific subtypes
DLBCLL-UNC/BL/DLBCL• Distinction of BL from morphologically similar
aggressive B-cell lymphoma has been problematic
• BL has characteristic GEP, but some DLBCL has similar GEP
• Most have complex karyotype often with dualtranslocation MYC and BCL-2
• Poor prognosis
![Page 29: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/29.jpg)
ASH 2011
![Page 30: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/30.jpg)
1. DLBCL, NOS
CD20HE Courtesy T. Tousseyn
![Page 31: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/31.jpg)
DLBCL, not otherwise specified (NOS)
• Most common
• May present in lymph node and/or extranodal
• Most common genetic aberrations:
– BCL6 gene (30% of cases)
– MYC (up to 10%)
– BCL2 translocations (especially in GCB-cellsubgroup)
![Page 32: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/32.jpg)
DLBCL, not otherwise specified (NOS)
• RNA gene-expression profile
– Staudt et al, N Engl J Med, 2002; 346 (25): 1937
![Page 33: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/33.jpg)
Alizadeh et al., Nature 403: 503, 2000
![Page 34: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/34.jpg)
DLBCL NOS: not one diseases
Germinal B-cell like (GCB) Activated B-cell like (ABC)
Cell of origin Germinal center B cell Post-germinal center B cell
Oncogenenicmechanism
• T (14;18) of BCL-2• Chr. 2p amplification of c-
rel locus
Constitutive activation of NF-KB
Clinical outcome Favorable: 60% 5-yr survival Poor: 35% 5-yr survival
![Page 35: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/35.jpg)
DLBCL: variants, subgroups and subtypes
• DLBCL: not otherwise specified• DLBCL: subtypes
– T-cell/histiocyte-rich large-cell lymphoma– EBV positive DLBCL of elderly
• DLBCL: specific anatomic sites– Primary mediastinal– Intravascular– Leg type– Primary DLBCL of CNS
• Borderline cases– Very often including “double hit” lymphoma’s
![Page 36: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/36.jpg)
![Page 37: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/37.jpg)
Prognostic factors in DLBCL“Clinical factors”
![Page 38: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/38.jpg)
International prognostic Index
Score Risk group
0-1 Low risk
2 Low-intermediate
3 High-intermediate
4-5 High-risk
Staging is defined according to the Ann Arbor system. The International Prognostic Index (IPI) and age-
adjusted is used for prognostic purposes.(2)
Risk factors: Age >60, serum LDH>normal range, ECOG performance status≥2, Ann Arbor stage III or IV,
number of extranodal sites >1
![Page 39: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/39.jpg)
Age adjusted International prognostic Index
Score Risk group
0 Low risk
1 Low-intermediate
2 High-intermediate
3 High-risk
Risk factors: serum LDH>normal range, ECOG performance status≥2, Ann Arbor stage III or IV
![Page 40: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/40.jpg)
![Page 41: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/41.jpg)
Overall Survival according to IPI score 6696 patients included in GELA randomized studies
IPI 0-1
IPI 2
IPI 3
IPI 4-5
Courtesy A. Bosly60 120OS (months)
![Page 42: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/42.jpg)
Case• A 72-year-old previously healthy man presented with acute abdominal
pain and a 15 kg weight loss. ECOG 1• Positron emission tomography demonstrated [18F]fluorodeoxyglucose-
avid mesenteric lymphadenopathy, with evidence of bowel compression near a 3x3 cm lymph node and lymphadenopathy upper diafragma.
• Bone marrow biopsy was negative, LDH normal, viral serology negative• ECOG:1
Age-adjusted IPI:1. Low2. low-intermediate3. High-intermediate4. High risk
CR rate:……………..5-yr OS:…………….
![Page 43: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/43.jpg)
Case• A 72-year-old previously healthy man presented with acute abdominal
pain and a 15 kg weight loss.• Positron emission tomography demonstrated [18F]fluorodeoxyglucose-
avid mesenteric lymphadenopathy, with evidence of bowel compression near a 3x3 cm lymph node and lymphadenopathy upper diafragma.
• Bone marrow biopsy was negative, LDH normal, viral serology negative• ECOG:1
Age-adjusted IPI: 1 risk factor (stage)
CR rate: 71%5-yr OS: 44%
Low-intermediate
![Page 44: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/44.jpg)
Smith A, Br J Haematol, 2010; 148:739-753
![Page 45: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/45.jpg)
Overall outcome in patients treated with R-CHOP
British Columbia
Sehn L H et al. Blood 2007;109:1857-1861
![Page 46: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/46.jpg)
Outcome according to the standard International Prognostic Index (IPI).
Sehn L H et al. Blood 2007;109:1857-1861
![Page 47: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/47.jpg)
Outcome according to the number of International Prognostic Index (IPI) factors.
Sehn L H et al. Blood 2007;109:1857-1861
![Page 48: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/48.jpg)
Outcome according to the revised International Prognostic Index (R-IPI).
Sehn L H et al. Blood 2007;109:1857-1861
![Page 49: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/49.jpg)
Alizadeh et al., Nature 403: 503, 2000
Biological prognostic factors by gene expression micro-arrays
![Page 50: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/50.jpg)
![Page 51: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/51.jpg)
Clinical study according to phenotype of diffuse large cells lymphomas
(Alizadeh, 2000)
![Page 52: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/52.jpg)
DLBCL: biological prognostic factors “immuno-histology”
![Page 53: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/53.jpg)
Ki67 100%CD10+
Bcl6-MuM1-
CMYC+
Courtesy T. Tousseyn
![Page 54: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/54.jpg)
DLBCL: Hans algorithm
![Page 55: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/55.jpg)
DLBCL: Hans algorithm
![Page 56: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/56.jpg)
Case• A 72-year-old previously healthy man presented with acute abdominal
pain and a 15 kg weight loss.• Positron emission tomography demonstrated [18F]fluorodeoxyglucose-
avid mesenteric lymphadenopathy, with evidence of bowel compression near a 3x3 cm lymph node and lymphadenopathy upper diafragma.
• Bone marrow biopsy was negative, LDH normal, viral serology negative• ECOG:1
CD10+BCL6-
CD10: negativeBCL-6: negative
Hans alogithm:…………
![Page 57: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/57.jpg)
OS for DLBCL patients with GCB/nonGCB DLBCL.
Ott G et al. Blood 2010;116:4916-4925
![Page 58: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/58.jpg)
Survival analysis of the validation set.
Choi W W et al. Clin Cancer Res 2009;15:5494-5502
OS by GEP
EFS by GEP
OS by alogorthm
EFS by algorithm
![Page 59: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/59.jpg)
Kaplan-Meier survival curves of event-free survival (EFS) of 62 DLBCL cases stratified
according to the IHC algorithm of: A, Choi et al.
Ballabio E et al. Clin Cancer Res 2010;16:3805-3806
![Page 60: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/60.jpg)
Prognosis and “Double-hit” lymphoma
• Term is used colloquiallty to refer to cases of lymphoma thatcontain translocations of both c-MYC gen at 8q24 and a second site, often BCL-2 gene at 18q21 (or BCL-6 gene)
• Most cases would be best considered “B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma (WHO 2008)
• Translocations involving c-MYC: 5-15 % of cases of DLBCL and confera worse prognosis after CHOP treatment
• Translocations only involving BCL-2 gene are seen in ± 30% of DLBCL cases and do not appear to impact survival
• However, BCL-2 translocated germinal center subtype DLBCL is associated with inferior outcome
• Combination between translocation c-MYC and translocation BCL-2 (± 5%): worse prognosis (median survival 6-18 months)
![Page 61: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/61.jpg)
Overall survival and progression-free survival of patients with DLBCL according to (A) the presence
of BCL2 translocations alone or concomitant MYC breaks stratified by GEP-defined subgroups; (B)
BCL2 translocations stratified with GEP subgroups in the vali...
Visco C et al. Haematologica 2013;98:255-263
![Page 62: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/62.jpg)
“Double-hit” and “double expression” lymphoma
• c-MYC translocation=increased c-MYC expression
• Overexpression of c-MYC without c-MYC translocation has also been described and is due to amplification
• Overexpression of c-MYC and overexpression of BCL-2 can beidentified by immunohistochemistry and is seen in 21-29% of patients
• Patients with double expression, but without the rearrangement have have also a lower CR rate and shorteroverall survival
![Page 63: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/63.jpg)
Overall (OS) and progression-free survival (PFS) of patients with diffuse large B-cell
lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and
prednisone according to presence of concurrent expression of MYC and BCL2 proteins (M...
Johnson N A et al. JCO 2012;30:3452-3459
![Page 64: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/64.jpg)
Case• A 72-year-old previously healthy man presented with acute abdominal
pain and a 15 kg weight loss.• Positron emission tomography demonstrated [18F]fluorodeoxyglucose-
avid mesenteric lymphadenopathy, with evidence of bowel compression near a 3x3 cm lymph node and lymphadenopathy upper diafragma.
• Bone marrow biopsy was negative, LDH normal, viral serology negative• No rearrangements of MYC en BCL2, EBER in situ negative
CD10+BCL6-MuM1-CMYC+ (>40%)
BCL2+ (>50%)
![Page 65: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/65.jpg)
Staging workup
• Patient history, physical examination• Performance status, B-symptoms• Complete blood count, chemistry including LDH• Screening for hepatitis B, C, HIV• Electrophoresis• Lymphe node biopsy (fine-needle aspirate is inadequate)• PET-CT scan• Bone marrow aspirate/biopsy (if negative PET-CT)• MRI for suspected CNS localisation• Spinal tap in patients with:
– Paranasal sinus, testicular, epidural, breast, bone marrow, presence of two or more extranodal sites, HIV
![Page 66: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/66.jpg)
Role of PET(CT) scan in DLBCL(J Clin Oncol, 2014, 27: 3048-3058 and 3059-3067)
• Initial staging √
– Leads to a change in stage in up to 20-40%
– This changes the treatment choise in 5-15%
• Interim PET for response assessment √
• Interim PET to direct treatment ?
• Restaging at completion of therapy √
• Screening for relapse: no
![Page 67: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/67.jpg)
Before after 1 CHOP-R after 4 CHOP-R after 6 CHOP-R
Tussentijdse opvolging van chemotherapie
![Page 68: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/68.jpg)
Early treatment evaluation with PET
2-year outcome
Study N Pet after… PET- PET+
Jerusalem (2000) 28 3 cycles 62% PFS 0% PFS
Spaepen (2002) 70 3 cycles 85% PFS 4% PFS
Kostakoglu (2002) 30 1 cycle 85% PFS <15% PFS
Haioun (2005) 90 2 cycles 82% EFS 43% EFS
Michaeel (2005) 121 2 cycles 87% PFS 34% PFS
![Page 69: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/69.jpg)
The use of interim PET to direct therapy
• If negative, continue treatment• High negative predictive value• Positive predictive value: 20-80%
– Inflammation, blood glucose level, tumor size, time form last treatment etc, interpretation of + versus –
• If positive, ???? Study!• Clinicians need:
– Simple positive or negative criteria– Easy to interpret– High positive and negative value
![Page 70: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/70.jpg)
Visual assessment of PET
• IHP: comparison between baseline mediastinal blood pool activity and lymphnodes sites of involvement
• Deauville score: negative 1-3, positive 4 or 5– Score 1: no uptake
– Score 2 uptake: ≤mediastinum
– Score 3 uptake: >mediastinum but ≤liver
– Score 4 uptake: >liver and new sites of disease
– Score X: new areas of uptake unlikely to be related to lymphoma
![Page 71: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/71.jpg)
Semiquantitive method: ∆𝑆𝑈𝑉max
• Baseline PET (PET0):– SUV max in the most active lesion
• Interim PET:– If (+): SUV max in the most active lesion
– If (-): SUV max in the area of PET0
• Calculation of % of SUV max reduction
• Optimal cut-off determined by ROC– 66% for ∆𝑆𝑈𝑉maxPET0-2
– 72.9% for ∆𝑆𝑈𝑉maxPET0-4
![Page 72: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/72.jpg)
Positive interim PET: Biopsy-proven method
• MSKCC: all patients with positive I-PET underwent biopsy
• Therapy was only changed in patients withbiopsy-proven lymphoma
• >80% of all biopsies were false-positive!!!
![Page 73: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/73.jpg)
Role of PET(CT) scan in DLBCL
• Restaging at completion of therapy– Standard of care– PET-: highly predictive of progression-free and overall survival– PET+: consolidation with radiotherapy ?
• Screening for relapse: no – Imaging-detected relapse is not associated with improved
survival– Very high number of false-positive results (80% of patients will
have unnecesary biopsies!)– Increased radiation exposure (risk of malignancies, especially in
younger patients?)– Expensive!
![Page 74: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/74.jpg)
Survival of patients with DLBCL
Goldsmith et al, Ann Hematol, 90: 165-171 (2011)
![Page 75: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/75.jpg)
Belgian guidelines newly diagnosedDLBCL
G. Verhoef, W. Schroyens, D. Bron, C. Bonnet, V. De Wilde, A. Van Hoof, A. Janssens, D. Dierickx, M.
André, E. Van Den Neste
Based on 2011 ESMO and NCCN version4.2011 and amended for the particular
Belgian context
![Page 76: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/76.jpg)
Limited stage
• Good riks patients (age-adjusted IPI 0, 1, non-bulky, no B-symptoms:
• R-CHOP 21 days x 6
or
• R-CHOP x 3 and involved field radiation
![Page 77: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/77.jpg)
Limited stage
• Young patients (<61 years) IPI low risk withburk or IPI low-intermediate:
• R-CHOP 21 days x 6 + IFR on bulk
• Young patients (age 18-59) with IPI 1:
• R-ACVBP x 4 and consolidation
![Page 78: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/78.jpg)
Advanced stage (age-adjusted IPI≥2, bulky>10cm, stage IIB, III-IV
• “Fit” advanced:– 8x R-CHOP-21 or 6x R-CHOP-14 + 2R
– Autologous transplantation after consolidation in selected patients or slow-responders: clinical trial
• Advanced older patients “unfit” for R-CHOP– Geriatric assessment
– Supportive care (anti-infectious, growth factors)
– Consider R-miniCHOPx6
– Pre-phase with steroids +/- vincristine
![Page 79: Diffuse large B-cell lymphomas - BHS](https://reader031.fdocuments.in/reader031/viewer/2022020707/61ff5a02c2a9fa29d76f3f58/html5/thumbnails/79.jpg)
CNS prophylaxis
• No consensus
• Paranasal sinus, testis, bone marrow and ≥ one extranodal sites: 4 doses of intrathecalMTX and/or arac
• LySA: IPI ≥1: 4 injections of MTX